On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) of its operating company Fresenius Kabi, has ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

Fresenius SE FRE0.03%increase; green up pointing triangle said it raised around 1.1 billion euros ($1.15 billion) after selling part of its Fresenius Medical Care FME 0.88%increase; green up ...

The disruption is expected to impact patient care, may require adjustments to the management of hemodialysis patients and ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

JD.com, City Office REIT, Fresenius Medical Care, Itron and Enersys have been highlighted in this Screen of The Week article.

The primary driver behind last 12 months revenue was the Fresenius Helios segment contributing a total revenue of €12.7b (58% ...

In a report released today, Graham Doyle from UBS maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report), with a price ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...